Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP- COVID)
What is REMAP-CAP?
A ‘Platform Trial’ that studies several different treatments at the same time, and assigns participants to treatment arms using a process called “response-adaptive randomization." To participate in the trial, patients must agree to be randomized to at least one of these treatment arms.
You may be eligible to participate if:
- You are an adult patient admitted to hospital with acute illness due to suspected or proven pandemic infection
- No more than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection
Participants will be randomized to specific domains:
- Antibiotic domain that evaluates commonly used antibiotics for severe pneumonia and COVID
- Antiviral domain that evaluates 5-day compared to 10-days treatments for patients with confirmed influenza and COVID
- Anticoagulation domain that evaluates two different doses of blood thinners to prevent blood clots for patients with COVID
Follow up:
- You be will followed daily while in hospital for up to 28 days. Follow-ups also occur on day 90 and day 180.
For more information, contact:
Critical Care Research team
Telephone: 416-480-6100 ext. 85426/1719 or pagers 7945/6873
Dr. Robert Fowler (Principal Investigator)
Telephone: 416-480-6100 ext: 7471, pager: 8609
